Ascendis Pharma A/S (FRA:A71)
181.00
+3.00 (1.69%)
Last updated: Dec 1, 2025, 8:19 AM CET
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 213.63M EUR in the quarter ending September 30, 2025, with 269.40% growth. This brings the company's revenue in the last twelve months to 646.55M, up 97.46% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
646.55M
Revenue Growth
+97.46%
P/S Ratio
17.14
Revenue / Employee
635.74K
Employees
1,017
Market Cap
11.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
Ascendis Pharma News
- 6 days ago - US FDA extends review of Ascendis Pharma's therapy for children with dwarfism - Reuters
- 6 days ago - Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewsWire
- 13 days ago - Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | ASND Stock News - GuruFocus
- 14 days ago - Ascendis Pharma (ASND) Reports Positive Results from TransCon CNP Trial for Achondroplasia - GuruFocus
- 14 days ago - Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics - GlobeNewsWire
- 19 days ago - Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus
- 19 days ago - Q3 2025 Ascendis Pharma A/S Earnings Call Transcript - GuruFocus
- 19 days ago - Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript - Seeking Alpha